Funding The authors received no funding or financial support
The area has a well-developed healthcare infrastructure, major actors are present, the disease prevalence is high, and investments in research and development for novel medications to treat diabetes and obesity are expanding
Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease
Rationale and design of a multicenter chronic kidney disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD
Having a higher weight or other underlying conditions such as diabetes can lead to negative effects on muscles, tendons, and joints
Food and Drug Administration (FDA) or other major regulatory authorities for therapeutic use